Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
https://www.calliditas.se/en/calliditas-therapeutics-announces-full-fda-approval-of-tarpeyo-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-reduce-the-loss-of-kidney-function/
https://www.calliditas.se/en/calliditas-therapeutics-announces-full-fda-approval-of-tarpeyo-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-reduce-the-loss-of-kidney-function/
22/12 2023 07:55 exitnu 0
117493 Calliditas: Interview with CEO Renée Aguiar-Lucander
"Redeye interviews Callidias CEO Renée Aguiar-Lucander, after securing a full FDA approval for Tarpeyo."
https://www.redeye.se/research/968342/calliditas-interview-with-ceo-renee-aguiar-lucander-2
"Redeye interviews Callidias CEO Renée Aguiar-Lucander, after securing a full FDA approval for Tarpeyo."
https://www.redeye.se/research/968342/calliditas-interview-with-ceo-renee-aguiar-lucander-2
27/12 2023 11:26 exitnu 0117598 Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patien
https://www.prnewswire.com/news-releases/everest-medicines-announces-new-drug-application-acceptance-of-nefecon-in-taiwan-for-the-treatment-of-primary-iga-nephropathy-in-adult-patients-302022659.html
"SHANGHAI, Dec. 26, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon® has been accepted for review by the Taiwan Food and Drug Administration (TFDA) for the treatment of primary immunoglobulin A nephropathy (IgAN) in adult patients. Nefecon® was the first ever treatment for IgAN approved in U.S., European Union and mainland China. Everest expects approval of Nefecon® in Taiwan in 2024."
https://www.prnewswire.com/news-releases/everest-medicines-announces-new-drug-application-acceptance-of-nefecon-in-taiwan-for-the-treatment-of-primary-iga-nephropathy-in-adult-patients-302022659.html
"SHANGHAI, Dec. 26, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon® has been accepted for review by the Taiwan Food and Drug Administration (TFDA) for the treatment of primary immunoglobulin A nephropathy (IgAN) in adult patients. Nefecon® was the first ever treatment for IgAN approved in U.S., European Union and mainland China. Everest expects approval of Nefecon® in Taiwan in 2024."
